Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study.
Raffaele OrnelloFayyaz AhmedAndrea NegroAnna Maria MiscioAntonio SantoroAlicia AlpuenteAntonio RussoMarcello SilvestroSabina CevoliNicoletta BrunelliFabrizio VernieriLicia GrazziBaraldi CarloSimona GuerzoniAnna P AndreouGiorgio LambruIlaria FrattaleKatharina KammRuth RuscheweyhMarco RussoPaola TorelliElena FilatovaNina V LatyshevaAnna Gryglas-DworakMarcin StraburzynskiCalogera ButeraBruno ColomboMassimo FilippiPatricia Pozo-RosichPaolo MartellettiSimona SaccoPublished in: Pain and therapy (2021)
Our data suggest that patients with CM responding to BT-A during the first two cycles will likely benefit from the third cycle of treatment, while the probability that non-responders to the first two cycles start responding during the third cycle is low. These results can help guide the individual decision to stop or continue treatment after the second cycle in patients who have not responded to the first two cycles.